Mirum Pharmaceuticals (MIRM) financial statements
Mirum Pharmaceuticals reported revenue of $521M in fiscal 2025, up 128.5% a year over 4 years.
Net income was -$23M.
Free cash flow was $55M.
The diluted share count rose 337% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Mirum Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $19M | $77M | $186M | $337M | $521M |
| Cost of revenue | — | $0 | $2M | $12M | $47M | $82M | $100M |
| Gross profit | — | $0 | $17M | $65M | $139M | $255M | $421M |
| Research and development | $43M | $82M | $131M | $107M | $103M | $141M | $186M |
| Selling, general and admin | $12M | $23M | $59M | $89M | $146M | $202M | $257M |
| Operating income | -$55M | -$104M | -$173M | -$131M | -$109M | -$88M | -$22M |
| Interest expense | — | — | — | $16M | $15M | $14M | $14M |
| Pre-tax income | -$53M | -$103M | -$84M | -$142M | -$162M | -$87M | -$21M |
| Income tax | $21,000 | $6,000 | $37,000 | -$6M | $991,000 | $1M | $2M |
| Net income | -$53M | -$103M | -$84M | -$136M | -$163M | -$88M | -$23M |
| EPS (diluted) | -$4.58 | -$4.09 | -$2.77 | -$4.02 | -$4.00 | -$1.85 | -$0.47 |
| Diluted shares | 11M | 25M | 30M | 34M | 41M | 48M | 50M |
| Gross margin | — | — | 90.1% | 83.9% | 74.8% | 75.8% | 80.8% |
| Operating margin | — | — | -906.1% | -170.3% | -58.6% | -26.0% | -4.2% |
| Net margin | — | — | -438.9% | -176.0% | -87.7% | -26.1% | -4.5% |
Balance sheet
Fiscal years, from Mirum Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $117M | $232M | $157M | $152M | $286M | $280M | $383M |
| Receivables | — | $0 | $3M | $24M | $68M | $78M | $123M |
| Inventory | — | $0 | $2M | $6M | $22M | $22M | $25M |
| Total current assets | $119M | $236M | $167M | $190M | $388M | $393M | $550M |
| Property, plant and equipment | $1M | $1M | $981,000 | $914,000 | $706,000 | $1M | $2M |
| Total assets | $147M | $241M | $295M | $353M | $647M | $671M | $843M |
| Total current liabilities | $13M | $18M | $43M | $65M | $87M | $127M | $206M |
| Total liabilities | $16M | $69M | $174M | $211M | $398M | $445M | $528M |
| Shareholders' equity | $130M | $172M | $120M | $142M | $249M | $226M | $315M |
| Net debt | -$12M | -$142M | -$31M | -$28M | -$286M | -$223M | -$297M |
Cash flow
Fiscal years, from Mirum Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$39M | -$89M | -$133M | -$120M | -$71M | $10M | $56M |
| Capital spending | $281,000 | $225,000 | $24,000 | $278,000 | $109,000 | $993,000 | $954,000 |
| Free cash flow | -$40M | -$89M | -$133M | -$120M | -$71M | $9M | $55M |
| Stock-based compensation | $6M | $13M | $23M | $27M | $35M | $48M | $71M |
| Free cash flow margin | — | — | -693.8% | -156.3% | -38.1% | 2.8% | 10.5% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for MIRM.
Open MIRM in InvestinglyQuestions
What was Mirum Pharmaceuticals's revenue in 2025?
$521M in fiscal 2025, from its 10-K filing.
How much free cash flow does Mirum Pharmaceuticals generate?
$55M in fiscal 2025 (operating cash flow minus capital spending).
From Mirum Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.